Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Yusuke Narita und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Biological Products, Scleroderma, Systemic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Limited information is available on the use of biologics in patients with systemic sclerosis (SSc) or SSc-associated interstitial lung disease (SSc-ILD) in Japan. The types of biologics, treatment duration, treatment prior to biologics, concomitant treatment, and characteristics of patients receiving biologics were investigated.
Methods
We used a Japanese hospital claims database provided by Medical Data Vision Co. (2008–2021).
Results
In the database, 1186 of 34,207 SSc patients (3.5%) and 620 of 12,303 SSc-ILD patients (5.0%) received anti-interleukin-6 (anti-IL-6) drugs, anti-tumour necrosis factor (anti-TNF) drugs, abatacept, or rituximab. The most common were anti-IL-6 drugs [used in 35.5% of SSc patients and 38.5% of SSc-ILD patients (tocilizumab, 34.5% and 36.6%)], followed by anti-TNF drugs [31.3% and 26.5% (etanercept, 10.5% and 9.0%; others, <8%)], abatacept (17.5% and 20.6%), and rituximab (15.7% and 14.4%). Among SSc and SSc-ILD patients treated with anti-IL-6 drugs, anti-TNF drugs, or abatacept, the most common immunosuppressive drugs prior to initiation of biologics were methotrexate and tacrolimus. Approximately half of patients receiving anti-IL-6 drugs, anti-TNF drugs, or abatacept continued treatment beyond 1 year.
Conclusions
Our study indicates that off-label biologics have been used in a certain number of SSc or SSc-ILD patients in Japan, with tocilizumab the most common.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
Zitieren
APA
Narita, Y., Funatogawa, T., Mii, K., Adachi, H., Tamura, A., & Yamakido, S. (2023). Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database. Modern Rheumatology. https://doi.org/10.1093/mr/roac055
Vancouver
Narita Y, Funatogawa T, Mii K, Adachi H, Tamura A, Yamakido S. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database. Modern Rheumatology. 2023. doi:10.1093/mr/roac055
BibTeX
@article{Narita2023,
author = {Narita, Yusuke and Funatogawa, Takashi and Mii, Kazuma and Adachi, Hiroki and Tamura, Aya and Yamakido, Shinji},
title = {Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac055}
}
EUVIMED